Navigation Links
MabVax Therapeutics Receives $1.8 Million in a Phase 2 Small Business Innovation Research Program Award From the National Cancer Institute
Date:4/11/2011

herapy, the majority of these patients with recurrent sarcoma die as a result of further recurrences.  

The vaccine is designed to instruct the patient's immune system to make antibodies against the three ganglioside antigens present on the surface of sarcoma cells. The antibodies are expected to seek out and eliminate residual circulating cancer cells and micrometastases. The vaccine was developed at Memorial Sloan-Kettering Cancer Center (MSKCC) where preclinical and early clinical development work was completed in 2009.  MabVax exclusively licensed the sarcoma vaccine, along with additional vaccines targeting other neuroectodermal and epithelial cancers, from MSKCC in 2008.  

Additional information may be obtained by following the link to the clinicaltrials.gov website.

About MabVax Therapeutics, Inc.

MabVax Therapeutics, Inc. is a clinical stage biotechnology company focused on the development of vaccine and antibody based therapies to address the unmet medical need of preventing recurrent cancer. The company was formed to exploit key aspects of the work of Dr. Philip Livingston and colleagues at MSKCC who have developed cancer vaccines against gangliosides and other carbohydrate antigens that are the most extensively expressed antigenic targets on the cell surface of certain cancers. The company believes that passively administered or vaccine induced antibodies against selected tumor cell surface antigens are ideally suited for eradication of free tumor cells and micrometastases that remain after initial treatment and cause cancer recurrence.  The company plans to commercially develop vaccines against several different types of cancer over the coming years.  Concurrently, MabVax is creating a pipeline of monoclonal antibody products based on the protective immune responses generated by patients who have been immunized against targeted cancers. The company i
'/>"/>

SOURCE MabVax Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. MabVax Therapeutics Receives Small Business Innovation Research Program Award from the National Cancer Institute
2. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
3. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
4. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
5. BN ImmunoTherapeutics Announces Partnership With National Cancer Institute
6. Arno Therapeutics Announces Appointment of Brian Lenz, CPA as Chief Financial Officer
7. CV Therapeutics Announces Ranexa(R) Named Finalist for Prix Galien USA 2008 Award
8. CV Therapeutics Receives European Approval for the Brand Name Ranexa(R)
9. Nile Therapeutics, Inc. Reports 2008 Second Quarter Financial Results
10. Cell Therapeutics, Inc.s Second Quarter 2008 Financial Results
11. Logical Therapeutics Inc. Announces Results of Phase 1b Clinical Study of its Naproxen Prodrug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... ... 2015 , ... It is now possible to separate two common disorders: post-traumatic ... tomography (SPECT) according to researchers from Amen Clinics, UCLA, Thomas Jefferson University, and ... is believed to be the largest brain imaging study ever, will be published on ...
(Date:7/1/2015)... , ... July 01, 2015 , ... The next-generation sequencing ... key market segments, including the molecular diagnostics industry. BCC Research reveals in its new ... NGS-based tests, lower test costs, and a growing need for better diagnostics as part ...
(Date:7/1/2015)... July 1, 2015  Axovant Sciences Ltd. (NYSE: ... the treatment of dementia, today announced that the ... 22 at 5:45 p.m. EDT following its presentation ... International Conference 2015 (AAIC). The ... , Dr. Lawrence Friedhoff , Chief Development ...
(Date:7/1/2015)... 1, 2015 InferMed , ... will ... evidence-based clinical s olutions suite   ... information products and services, announced today the acquisition of  InferMed ... (CDS) technology company. InferMed,s Arezzo technology supports clinicians ...
Breaking Biology Technology:Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 2Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 3Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 4NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 2NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 3Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 2Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 3Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 2Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 3Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 4
... 2012   Proteonomix, Inc. (OTC/BB: PROT) announced today ... institutional investors, pursuant to which the Company has agreed ... stock at an aggregate purchase price of approximately $3.8 ... shares of Proteonomix common stock) and Series A, Series ...
... be the basis of a new type of solar cell, ... expect these structures will allow us to make better, more ... on the $100,000 grant. Fractals are patterns that repeat ... 1-50th the width of a human hair are themselves branched, ...
... SAN DIEGO, March 5, 2012 Cadence Pharmaceuticals, Inc. ... on in-licensing, developing and commercializing proprietary product candidates principally ... it will release its fourth quarter and full year ... 12, 2012. Cadence management will host ...
Cached Biology Technology:Proteonomix Announces a Private Placement of $3.8 Million 2Proteonomix Announces a Private Placement of $3.8 Million 3Proteonomix Announces a Private Placement of $3.8 Million 4
(Date:6/23/2015)... , June 23, 2015   MedNet ... that supports the entire spectrum of clinical research, ... ™ , the company,s intuitive, flexible ... awarded a Silver 2015 Stevie® Award by the ... Products & Services Website category.  The American Business ...
(Date:6/23/2015)... , June 23, 2015   Valencell, ... the results of a recent study that illustrates ... the wrist during activity. In a study conducted ... compared along with the Apple Watch against a ... heart rate during activity. The study demonstrated that ...
(Date:6/18/2015)... , June 18, 2015 This report analyzes ... by the following Product Segments, which includes Immunoassay Analyzers ... Immunoassay Systems, Radio Immunoassay Systems, and Nephelometric Immunoassay Systems. ... Canada , Japan ... , Latin America , and ...
Breaking Biology News(10 mins):MedNet Solutions' iMedNet eClinical Wins Silver Stevie Award 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 3Global Immunoassay Systems Market 2Global Immunoassay Systems Market 3Global Immunoassay Systems Market 4Global Immunoassay Systems Market 5Global Immunoassay Systems Market 6Global Immunoassay Systems Market 7Global Immunoassay Systems Market 8Global Immunoassay Systems Market 9Global Immunoassay Systems Market 10Global Immunoassay Systems Market 11Global Immunoassay Systems Market 12Global Immunoassay Systems Market 13Global Immunoassay Systems Market 14Global Immunoassay Systems Market 15Global Immunoassay Systems Market 16Global Immunoassay Systems Market 17Global Immunoassay Systems Market 18Global Immunoassay Systems Market 19Global Immunoassay Systems Market 20Global Immunoassay Systems Market 21Global Immunoassay Systems Market 22Global Immunoassay Systems Market 23Global Immunoassay Systems Market 24Global Immunoassay Systems Market 25Global Immunoassay Systems Market 26Global Immunoassay Systems Market 27Global Immunoassay Systems Market 28Global Immunoassay Systems Market 29
... Friedberg,s unsurpassed expertise in managing digital risk and uncovering digital ... Mountain Capital to fuel and accelerate the company,s growth. ... at the perfect time," says Eric Friedberg , Co-President ... the firm plans to expand to key markets in the ...
... than two kilometres down in the inky depths of ... of Vancouver Island, Canada has just made scientific and ... and most advanced cabled ocean observatoryhas been completed. ... aboard the research vessel T.G. Thompson after four weeks ...
... drinking water from the sea to prepare for a ... ship hull designs for the best fuel efficiency, are ... million research project announced today (Friday 15 October) at ... Jason Reese of the University,s Faculty of Engineering has ...
Cached Biology News:Stroz Friedberg Amplifying Growth with $115MM New Mountain Capital Investment 2Stroz Friedberg Amplifying Growth with $115MM New Mountain Capital Investment 3Stroz Friedberg Amplifying Growth with $115MM New Mountain Capital Investment 4Team completes world-first ocean observatory 2£2.4m boost for nano research into global challenges 2